These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 27339736

  • 1. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.
    Saxena K, Lalezari S, Oldenburg J, Tseneklidou-Stoeter D, Beckmann H, Yoon M, Maas Enriquez M.
    Haemophilia; 2016 Sep; 22(5):706-12. PubMed ID: 27339736
    [Abstract] [Full Text] [Related]

  • 2. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial.
    Ljung R, Kenet G, Mancuso ME, Kaleva V, Rusen L, Tseneklidou-Stoeter D, Michaels LA, Shah A, Hong W, Maas Enriquez M, investigators of the LEOPOLD Kids Trial.
    Haemophilia; 2016 May; 22(3):354-60. PubMed ID: 26663410
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of BAY 81-8973 for surgery in previously treated patients with haemophilia A: results of the LEOPOLD clinical trial programme.
    Oldenburg J, Windyga J, Hampton K, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Maas Enriquez M.
    Haemophilia; 2016 May; 22(3):349-53. PubMed ID: 26931631
    [Abstract] [Full Text] [Related]

  • 4. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II).
    Kavakli K, Yang R, Rusen L, Beckmann H, Tseneklidou-Stoeter D, Maas Enriquez M, LEOPOLD II Study Investigators.
    J Thromb Haemost; 2015 Mar; 13(3):360-9. PubMed ID: 25546368
    [Abstract] [Full Text] [Related]

  • 5. Chromogenic assay for BAY 81-8973 potency assignment has no impact on clinical outcome or monitoring in patient samples.
    Kitchen S, Katterle Y, Beckmann H, Maas Enriquez M.
    J Thromb Haemost; 2016 Jun; 14(6):1192-9. PubMed ID: 27002680
    [Abstract] [Full Text] [Related]

  • 6. Safety and efficacy of BAY 94-9027, a prolonged-half-life factor VIII.
    Reding MT, Ng HJ, Poulsen LH, Eyster ME, Pabinger I, Shin HJ, Walsch R, Lederman M, Wang M, Hardtke M, Michaels LA.
    J Thromb Haemost; 2017 Mar; 15(3):411-419. PubMed ID: 27992112
    [Abstract] [Full Text] [Related]

  • 7. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years.
    Mahlangu J, Lopez Fernandez MF, Santagostino E, Lalezari S, Tseneklidou-Stoeter D, Beckmann H, Church N.
    Eur J Haematol; 2020 Jun; 104(6):594-601. PubMed ID: 32112434
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of prophylaxis with BAY 81-8973 in Chinese patients with severe haemophilia A enrolled in the LEOPOLD II trial.
    Yang R, Sun J, Zhao Y, Wang X, Wu D, Tseneklidou-Stoeter D, Wu J, Church N.
    Haemophilia; 2019 May; 25(3):e153-e158. PubMed ID: 30993836
    [Abstract] [Full Text] [Related]

  • 9. Clinical evaluation of glycoPEGylated recombinant FVIII: Efficacy and safety in severe haemophilia A.
    Giangrande P, Andreeva T, Chowdary P, Ehrenforth S, Hanabusa H, Leebeek FW, Lentz SR, Nemes L, Poulsen LH, Santagostino E, You CW, Clausen WH, Jönsson PG, Oldenburg J, Pathfinder™2 Investigators.
    Thromb Haemost; 2017 Jan 26; 117(2):252-261. PubMed ID: 27904904
    [Abstract] [Full Text] [Related]

  • 10. BAY 81-8973 (Octocog Alfa; Kovaltry®): A Review in Haemophilia A.
    Keating GM.
    BioDrugs; 2016 Oct 26; 30(5):453-459. PubMed ID: 27577234
    [Abstract] [Full Text] [Related]

  • 11. Safety and efficacy of a glycoPEGylated rFVIII (turoctocog alpha pegol, N8-GP) in paediatric patients with severe haemophilia A.
    Meunier S, Alamelu J, Ehrenforth S, Hanabusa H, Abdul Karim F, Kavakli K, Khodaie M, Staber J, Stasyshyn O, Yee DL, Rageliene L.
    Thromb Haemost; 2017 Aug 30; 117(9):1705-1713. PubMed ID: 28692108
    [Abstract] [Full Text] [Related]

  • 12. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.
    Young G, Mahlangu J, Kulkarni R, Nolan B, Liesner R, Pasi J, Barnes C, Neelakantan S, Gambino G, Cristiano LM, Pierce GF, Allen G.
    J Thromb Haemost; 2015 Jun 30; 13(6):967-77. PubMed ID: 25912075
    [Abstract] [Full Text] [Related]

  • 13. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis.
    Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML.
    Thromb Haemost; 2021 Aug 30; 121(8):1079-1086. PubMed ID: 33296943
    [Abstract] [Full Text] [Related]

  • 14. PROTECT VIII Kids: BAY 94-9027 (PEGylated Recombinant Factor VIII) safety and efficacy in previously treated children with severe haemophilia A.
    Santagostino E, Kenet G, Fischer K, Biss T, Ahuja S, Steele M.
    Haemophilia; 2020 May 30; 26(3):e55-e65. PubMed ID: 32212300
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetic properties of BAY 81-8973, a full-length recombinant factor VIII.
    Shah A, Delesen H, Garger S, Lalezari S.
    Haemophilia; 2015 Nov 30; 21(6):766-71. PubMed ID: 25952661
    [Abstract] [Full Text] [Related]

  • 16. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A.
    Zhao Y, Hu Y, Jin J, Zhao X, Wang X, Wu R, Wu D, Yang R, Yang F, Hu Q, Wang J, Fang H, Engl W.
    Clin Appl Thromb Hemost; 2021 Nov 30; 27():1076029621989811. PubMed ID: 33587652
    [Abstract] [Full Text] [Related]

  • 17. BAY 94-9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results.
    Lalezari S, Reding MT, Pabinger I, Holme PA, Negrier C, Chalasani P, Shin HJ, Wang M, Tseneklidou-Stoeter D, Maas Enriquez M.
    Haemophilia; 2019 Nov 30; 25(6):1011-1019. PubMed ID: 31621991
    [Abstract] [Full Text] [Related]

  • 18. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A.
    Tiede A, Oldenburg J, Lissitchkov T, Knaub S, Bichler J, Manco-Johnson MJ.
    Haemophilia; 2016 May 30; 22(3):374-80. PubMed ID: 26582282
    [Abstract] [Full Text] [Related]

  • 19. Safety and efficacy of sucrose-formulated full-length recombinant factor VIII: experience in the standard clinical setting.
    Musso R, Santagostino E, Faradji A, Iorio A, van der Meer J, Ingerslev J, Lambert T, Maas-Enriquez M, Gorina E, KOGENATE Bayer European PMS Study Group.
    Thromb Haemost; 2008 Jan 30; 99(1):52-8. PubMed ID: 18217134
    [Abstract] [Full Text] [Related]

  • 20. Continued benefit demonstrated with BAY 81-8973 prophylaxis in previously treated children with severe haemophilia A: Interim analysis from the LEOPOLD Kids extension study.
    Kenet G, Ljung R, Rusen L, Kerlin BA, Blanchette V, Saulytė Trakymienė S, Uscatescu V, Beckmann H, Tseneklidou-Stoeter D, Church N.
    Thromb Res; 2020 May 30; 189():96-101. PubMed ID: 32197139
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.